Skip to main content

Advertisement

SpringerLink
Log in

Anterior Gradient 2 is a Poor Outcome Indicator in Luminal Breast Cancer

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Recent data have shown anterior gradient 2 (AGR2) to be a novel oncogene overexpressed in luminal breast cancers. However, many studies only focused on its relationship with treatment resistance, and the clinical relevance of AGR2 has not been widely evaluated.

Methods

AGR2 expression in a cohort of breast cancer was correlated with the clinicopathologic features, biomarker expression, and patient survival.

Results

AGR2 expression correlated with lower grade (p = 0.002) and absence of necrosis (p = 0.001) and was most highly expressed in luminal cancers (p < 0.001). Correspondingly, AGR2 correlated positively with estrogen receptor, progesterone receptor, and androgen receptor (p < 0.001) and negatively with epidermal growth factor receptor (p = 0.002) and CK5/6 (p < 0.001). AGR2 was an independent unfavorable disease-free survival prognostic factor in patients with hormone therapy (hazard ratio 2.537, p = 0.023). Interestingly, it was also an independent adverse disease-free survival prognostic factor in node-positive luminal cancers (hazard ratio 3.381, p = 0.016). AGR2 expression was higher in nodal metastasis than the corresponding primary tumors in luminal cancers (p = 0.023).

Conclusions

The prognostic impact of AGR2 expression could be related to treatment outcome in estrogen receptor–positive breast cancers and/or its metastasis-promoting effects. It could be an important tumor biomarker and negative prognostic factor potentially exploitable in clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Benham AM. The protein disulfide isomerase family: key players in health and disease. Antioxid Redox Signal. 2012;16:781–9.

    Article  CAS  PubMed  Google Scholar 

  2. Fletcher GC, Patel S, Tyson K, et al. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor–positive breast tumours and interact with metastasis gene C4.4a and dystroglycan. Br J Cancer. 2003;88:579–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Maresh EL, Mah V, Alavi M, et al. Differential expression of anterior gradient gene AGR2 in prostate cancer. BMC Cancer. 2010;10:680.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Park K, Chung YJ, So H, et al. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med. 2011;43:91–100.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Ramachandran V, Arumugam T, Wang H, Logsdon CD. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res. 2008;68:7811–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Pizzi M, Fassan M, Balistreri M, Galligioni A, Rea F, Rugge M. Anterior gradient 2 overexpression in lung adenocarcinoma. Appl Immunohistochem Mol Morphol. 2012;20:31–6.

    Article  CAS  PubMed  Google Scholar 

  7. Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res. 2008;68:492–7.

    Article  CAS  PubMed  Google Scholar 

  8. Fritzsche FR, Dahl E, Pahl S, et al. Prognostic relevance of AGR2 expression in breast cancer. Clin Cancer Res. 2006;12:1728–34.

    Article  CAS  PubMed  Google Scholar 

  9. Thompson DA, Weigel RJ. hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem Biophys Res Commun. 1998;251:111–6.

    Article  CAS  PubMed  Google Scholar 

  10. Vanderlaag KE, Hudak S, Bald L, et al. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin. Breast Cancer Res. 2010;12:R32.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res. 2005;65:3796–805.

    Article  CAS  PubMed  Google Scholar 

  12. Barraclough DL, Platt-Higgins A, de Silva Rudland S, et al. The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol. 2009;175:1848–57.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Hrstka R, Brychtova V, Fabian P, Vojtesek B, Svoboda M. AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients. Dis Markers. 2013;35:207–12.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Hrstka R, Nenutil R, Fourtouna A, et al. The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene. 2010;29:4838–47.

    Article  CAS  PubMed  Google Scholar 

  15. Innes HE, Liu D, Barraclough R, et al. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer. 2006;94:1057–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Lakhani SR, Ellis IO, Schnitee SJ, Tan PH, van de Vijver MJ, eds. World Health Organisation classification of tumors of the breast. 4th ed. Lyon: IARC Press; 2012.

    Google Scholar 

  17. Ni YB, Tsang JY, Chan SK, Tse GM. A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma. Ann Surg Oncol. 2014;21:2928–33.

    Article  PubMed  Google Scholar 

  18. Tsang JY, Ni YB, Chan SK, et al. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers. Ann Surg Oncol. 2014;21:2218–28.

    Article  PubMed  Google Scholar 

  19. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, 2011. Ann Oncol. 2011;22:1736–47.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer. 2005;43:249–59.

    Article  CAS  PubMed  Google Scholar 

  21. Liao GS, Chou YC, Hsu HM, Dai MS, Yu JC. The prognostic value of lymph node status among breast cancer subtypes. Am J Surg. (In press).

  22. Valladares-Ayerbes M, Diaz-Prado S, Reboredo M, et al. Bioinformatics approach to mRNA markers discovery for detection of circulating tumor cells in patients with gastrointestinal cancer. Cancer Detect Prev. 2008;32:236–50.

    Article  CAS  PubMed  Google Scholar 

  23. Marin-Aguilera M, Mengual L, Ribal MJ, et al. Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer. Urology. 2012;79:249.e9–15.

    Article  Google Scholar 

  24. da Costa A, Lenze D, Hummel M, Kohn B, Gruber AD, Klopfleisch R. Identification of six potential markers for the detection of circulating canine mammary tumour cells in the peripheral blood identified by microarray analysis. J Comp Pathol. 2012;146:143–51.

    Article  PubMed  Google Scholar 

  25. Smirnov DA, Zweitzig DR, Foulk BW, et al. Global gene expression profiling of circulating tumor cells. Cancer Res. 2005;65:4993–7.

    Article  CAS  PubMed  Google Scholar 

  26. Hrstka R, Murray E, Brychtova V, Fabian P, Hupp TR, Vojtesek B. Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2. Cancer Lett. 2013;333:187–93.

    Article  CAS  PubMed  Google Scholar 

  27. . Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK. Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim Biophys Acta. 2011;1815:224–40.

    PubMed Central  CAS  PubMed  Google Scholar 

  28. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009;9:874–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China

    Maribel D. Lacambra DPSP, Julia Y. S. Tsang PhD, Yun-Bi Ni MMSc & Gary M. Tse FRCPC

  2. Department of Pathology, Kwong Wah Hospital, Hong Kong, China

    Siu-Ki Chan FHKCPath

  3. Department of Pathology, Singapore General Hospital, Singapore, Singapore

    Puay Hoon Tan FRCPA

Authors
  1. Maribel D. Lacambra DPSP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Y. S. Tsang PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yun-Bi Ni MMSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Siu-Ki Chan FHKCPath
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Puay Hoon Tan FRCPA
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gary M. Tse FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary M. Tse FRCPC.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 204 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lacambra, M.D., Tsang, J.Y.S., Ni, YB. et al. Anterior Gradient 2 is a Poor Outcome Indicator in Luminal Breast Cancer. Ann Surg Oncol 22, 3489–3496 (2015). https://doi.org/10.1245/s10434-015-4420-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-4420-8

Keywords

Search

Navigation